If you made any changes in Pure these will be visible here soon.

Personal profile

Biography

Colin graduated from University of Edinburgh, with Honours in Pharmacology with Industrial Experience (Pharmagene).  Afterwards he gained five-years experience working in industry as a functional pharmacologist for Asterand Biosceince, conducting tissue bath and myography pharmacology studies in human samples. He obtained his doctorate under the supervision of Prof Ajay Shah at BHF Cardiovascular Centre of Excellence, King’s College London, as part of the augural cohort on British Heart Foundation 4-year PhD program. His work investigated the “Influence of endothelial NADPH oxidase on cardiac fibrosis and remodelling in the hypertensive heart.”  utilising murine cardiovascular techniques such as pressure-volume loops, echocardiography and telemetry.  Subsequently, Colin moved to the USA, conducted post-doctoral training with Richard Cohen and Reiko Matsui at the Whitaker Cardiovascular Institute, Boston University investigating redox signalling in neovascularisation in type-2 diabetes.

In 2014 he was awarded a highly competitive Marie Skłodowska-Curie International Incoming Fellowship to move back to the UK and transfer in vivo cardiovascular phenotyping techniques to Aston Medical School with Prof Asif Ahmed. Where he developed a successful multidisciplinary PhD training program for Horizon2020 Innovative training network, iPLACENTA.  Involving a collaborative network between 11 academic, clinical and industry institutes across Europe training 15 PhD students.  In 2017, he received the Aston University prize for research.

Colin joined the faculty as a lecturer in Systems Medicine, School of Medicine, University of Dundee in March 2018 and bringing the coordination of iPLACENTA-ITN to University of Dundee.   Colin’s research focuses on the pathophysiological role of redox signalling in cardiovascular disease including preeclampsia and peripheral artery disease.   

Research

Dr Murdoch’s research aims to understand how redox signalling affects cardiovascular pathology, focusing on signalling in the endothelium and currently funded by Hoizon2020 Marie Curie and Tenovus.

It is now widely accepted that oxidative stress does not only induce cellular damage but is involved in intricate signalling pathways in physiology and pathophysiology.  A major way in which redox signalling occurs is through oxidative post-translational modifications.  Work in the Murdoch lab combines cell specific transgenics and in vivo phenotyping techniques with molecular biology to decipher how redox signalling regulate cardiovascular disease, such as cardiac diastolic dysfunction, ischemic neovascularisation and preeclampsia.

 The current focus of research in the Murdoch lab involves investigating how oxidative post-translational modification of thiols contribute to the preeclampsia phenotype. In pregnancy, oxidative stress is explicitly linked preeclampsia, with high levels measurable both in the placenta and maternal circulation.  Yet, it is poorly understood which proteins/pathways are modified by oxidative stress and how oxidative post-translational modifications can modify the preeclampsia phenotype.  Dysregulation of angiogenic factors, such as high soluble Flt-1 (sFlt-1) levels are established as major culprits in the development of the ‘preeclampsia phenotype’ of high maternal blood pressure and proteinurea, associated with increased endothelial dysfunction and prevalence to cardiovascular disease.  

Current Research Projects

iPLACENTA

Dr Murdoch is the coordinator and founder of iPLACENTA, a €3.9 million Horizon 2020 innovative training network (ITN).   A multi-disciplinary network of 11 European partners delivering post-graduate training for 15 Early stage researchers (ESRs/Ph,D).  The principal research aim of iPLACENTA is to improve the ability to study, model and visualise the placenta to enhance investigation and prognosis of complicated pregnancies such as preeclampsia and intrauterine growth restriction.   Integrating organ-chip technology and mathematical modelling, with innovation in visualising and assessing placenta health in the clinic and pre-clinical models.   The research will interconnect to unlock the complexity of placental disease, providing mechanistic clues for complex diseases, new ways to model placenta function, validate novel clinical diagnostic tools and characterise in vivo pre-clinical models.   The PhD training programme aims to equip the ESRs with the necessary skills to meet the challenges of cutting-edge translational research alongside topics such as OpenScience, entrepreneurship, project management and business skills.   See www.iplacenta.eu

Mr Lukas Markwalder PhD candidate:  Generation of endoscopic laser speckle imaging probe for in vivo assessment of placental vascularisation.  Involving a multidisciplinary collaboration with industry, Dr Rodney Gush Moor Instruments, and cross school Dr Nikola Krstajic (School of Engineering).  Also including collaboration with Prof Fasiel Khan (Systems Medicine)

Ms Agathe Lermant, PhD candidate: Generation and validation of in vitro models of preclampsia using iPSC-derived trophoblast and endothelial cells.  This project will support the validation of placental on a chip made by our industry collaborator Mimetas.

Ms Mirren Augustin iPLACENTA project manager:  Mirren is the project manager for the iPLACENTA consortium and is based at University of Dundee ensuring smooth running of the Horizon 2020 project.

Current Undergraduate and Post-Graduate Project Students

Mr Peter Geary MSci (Sept 2019- May) 

Mr Matthew Scott (DCat summer student)

Ms Meghan Dawson (BioMed Hons 4th year project)

 

Previous Post-Graduate and Undergraduate Rotation students

Jack Hanna (MRC-DTP PhD  1st year rotation) - Investigating thiol regualtion of  the spliceosome 

Jack Morris (BioMed honours 4th year project) -  The role of Gluatredoxin on VEGF signalling

Ioannis Efstathiou (BMSc) - Soluble VEGFR1 shedding in endothelial cells

 

 

Dr Murdoch has received previous funding from Diabetes UK, and EU Marie Curie framework 7.

Applications are accepted all year round for self-funded or government funded PhDs and post-doctoral opportunities.  Please send letter of interest with CV to Dr Murdoch.

Research interests

Research in the Murdoch lab utlisies a combination of in vivo, ex vivo and molecular technquies to model and characterise cardiovascular function including:

In vivo cardiovascular techniques

Ambulatory aortic blood pressure assessment by telemetry implantation (DSI)

Cardiac function – pressure-volume loops through left ventricular microcatheter insertion (Transonic)

Blood flow measurements – Laser Doppler (Moor Instruments)

 

Cardiovascular models

Left ventricular hypertrophy through minimal invasive transverse aortic constriction or Angiotensin II osmotic pumps implantation.

Preeclampsia Phenotype -reduced uterine placental perfusion (RuPP).

Neovascularisation- hind limb ischemia and corneal micropocket assay.

Ex vivo techniques

Blood vessel (and tissue) wire myography for measurement of vascular tone (DMT)

Primary murine cardiac microvascular endothelial cells isolation via magnetic bead technology (Miltenyi Biotec)

Neonatal retinal vascularisation

Inflammatory cell adhesion to endothelial cells in flow chamber

 

Cellular and Molecular Biology

Biotin switch for identification of revisable thiols.

RNA Immunoprecipitation (rIP Assay).

Endothelial cell migration and network formation.

Immunohistochemistry measuring:-, cardiac fibrosis, muscle capillary density and inflammatory cell infiltration

Teaching

Dr Colin Murdoch provides teaches at level 4 and is also

Course co-lead Level 4 BSc (Honours) Heart & Circulation Physiology (BS42019)

Course deputy Level 4 BSc (Honours). Cardiovascular Pharmacology (BS42021)

Course Lead BMSc (Hon) in Cardiovascular & Diabetes Medicine 

Dr Murdoch also supervises various rotation project involving basic cardiovascular research for the following programmes:  BSc Honours final year project students, MSCi , DCat, BMSc and MRC-DTP. 

Education/Academic qualification

Doctor of Medicine, King's College London

1 Nov 20041 Apr 2008

Bachelor of Science, University of Edinburgh

1 Sep 19961 Sep 2000

External positions

EU ITN coordinator

1 Jan 20181 Feb 2022

Keywords

  • RM Therapeutics. Pharmacology
  • QP Physiology
  • RZ Other systems of medicine
  • Cardiovascular

Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 1 Similar Profiles
NADPH Oxidase Medicine & Life Sciences
Glutaredoxins Medicine & Life Sciences
Fibrosis Medicine & Life Sciences
Reactive Oxygen Species Medicine & Life Sciences
Endothelial Cells Medicine & Life Sciences
Oxidation-Reduction Medicine & Life Sciences
Vascular Endothelial Growth Factor Receptor-1 Medicine & Life Sciences
Angiotensin II Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2018 2021

Research Output 2004 2019

14 Citations (Scopus)
12 Downloads (Pure)

Distinct regulatory effects of myeloid cell and endothelial cell Nox2 on blood pressure

Sag, C. M., Schnelle, M., Zhang, J., Murdoch, C. E., Kossmann, S., Protti, A., Santos, C. X. C., Sawyer, G. J., Zhang, X., Mongue-Din, H., Richards, D. A., Brewer, A. C., Prysyazhna, O., Maier, L. S., Wenzel, P., Eaton, P. J. & Shah, A. M., 15 Mar 2017, In : Circulation. 135, 22, p. 2163-2177 15 p.

Research output: Contribution to journalArticle

Open Access
File
Myeloid Cells
Endothelial Cells
Blood Pressure
Angiotensin II
NADPH Oxidase
9 Citations (Scopus)
16 Downloads (Pure)

Redox regulation of ischemic limb neovascularization - What we have learned from animal studies

Matsui, R., Watanabe, Y. & Murdoch, C. E., Aug 2017, In : Redox Biology. 12, p. 1011-1019 9 p.

Research output: Contribution to journalReview article

Open Access
File
Glutaredoxins
Oxidants
Oxidation-Reduction
Animals
Extremities
5 Downloads (Pure)

IL-33 induction and signaling are controlled by glutaredoxin-1 in mouse macrophages

Weinberg, E. O., Ferran, B., Tsukahara, Y., Hatch, M. M. S., Han, J., Murdoch, C. E. & Matsui, R., 25 Jan 2019, In : PLoS ONE. 14, 1, 15 p., e0210827.

Research output: Contribution to journalArticle

Open Access
File
Glutaredoxins
Macrophages
interleukins
macrophages
mice
3 Citations (Scopus)
11 Downloads (Pure)

Cardiac fibrosis can be attenuated by blocking the activity of transglutaminase 2 using a selective small-molecule inhibitor

Wang, Z., Stuckey, D. J., Murdoch, C. E., Camelliti, P., Lip, G. Y. H. & Griffin, M., 27 Apr 2018, In : Cell Death and Disease. 9, 6, p. 613 12 p., 613.

Research output: Contribution to journalArticle

Open Access
File
Fibrosis
Myofibroblasts
transglutaminase 2
Heart Rupture
Angiotensin II
13 Downloads (Pure)

Therapeutic Angiogenesis of Chinese Herbal Medicines in Ischemic Heart Disease: A Review

Guo, D., Murdoch, C. E., Liu, T., Qu, J., Jiao, S., Wang, Y., Wang, W. & Chen, X., 26 Apr 2018, In : Frontiers in Pharmacology. 9

Research output: Contribution to journalReview article

Open Access
File

Prizes

Aston Achievement Awards Excellent Research

Colin Murdoch (Recipient), 1 Jan 2017

Prize: Prize (including medals and awards)

Marie Skłodowska-Curie International Incoming Fellow

Colin Murdoch (Recipient), 1 May 2014

Prize: Fellowship awarded competitively

Pre-Eclampsia
Medical Schools
Microsurgery
Pre-Eclampsia
Transgenic Mice
Blood Vessels
Cardiovascular Diseases